What do the exposure tests show?

What supports absolute wording about ozone under every condition a buyer would reasonably infer?

The company's ozone statement is about what the filter gives off, and it rests on the filter having nothing that could generate ozone.

NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The Statement of Classification states at 2.4 that in use the ventilation system's own fan moves air through the filter, that the filter is passive, that it draws no power, and that it has no power supply, electrode, lamp or reservoir, and that it generates no ozone and emits nothing into the air passing through it. The label for the NanoFlashing™ Air Filter states that no power is required and that there is no by-product such as ozone. The polarity is a positive electric charge at rest, and the charge is measured on every production run.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, sections 2.2 and 2.4, issued by NF Technical Products Inc.; NanoFlashing™ Air Filter label.

Reviewed on 6 October 2026.

What information addresses released material or byproducts under foreseeable damage and wear?

What the company says about release is about the air: the Statement of Classification states at 2.4 that the filter generates no ozone and emits nothing into the air passing through it, and that the air leaving the filter has had nothing added to it. A charge is a physical property. It is not a substance or a mixture of substances.

A statement that nothing was detected belongs to the report that measured it, with the capability of the measurement it used, and the Terms of Use state: “A reported result describes only what the identified test found.” A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.

What evidence addresses skin-contact compatibility for the intended garment and wearing conditions?

For skin contact, the company names Product Safety Labs, Study 65323 (skin irritation) and Study 65324 (dermal sensitisation), and OEKO-TEX® Standard 100, Product Class II, Certificate 17.0.25812; it publishes no result for a particular garment under its wearing conditions.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sample. Each of the four covers one endpoint. Product Safety Labs, Study 65323 was completed on 16 February 2024 and Study 65324 on 31 January 2024; each result describes that sample under that study’s conditions. The Validation page also states that NanoFlashing™ is certified to OEKO-TEX® Standard 100, Product Class II, the class for products in direct contact with skin, and names OEKO-TEX Service GmbH, Certificate 17.0.25812.

Each of those studies describes one endpoint, on that sample, under those conditions. Irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report. Certificate 17.0.25812 can be checked at source in OEKO-TEX’s public label check.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; OEKO-TEX Label Check, read 19 September 2026, https://www.oeko-tex.com/en/label-check.

Reviewed on 6 October 2026.

Which complete reports address eye and inhalation exposure for the exact finished material and use at issue?

The published record names four health-effects studies, and none of them is an eye study or an inhalation study.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A copy may be made available on our review of the request.

NanoFlashing™ is passive. It generates no ozone, releases nothing, and adds nothing to what passes through. The air leaving the filter has had nothing added to it.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 6 October 2026.

What evidence bridges the exposure assessment when a substrate, supplier, process or assembly component changes?

A study covers the article it tested, so a change of substrate, supplier, process or assembly is assessed again by the party that makes the changed article.

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.” They also state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use,” and: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The About page states that development runs configuration by configuration, and that each partner controls what is said about the work.

The studies the company names are Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, each completed in 2024 and each run on a sample. What a complete appliance gives off is a matter for the maker of that appliance, and C-POLAR publishes no assessment of one. A copy may be made available on our review of the request.

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/; C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Validation, https://cpolar.tech/validation/.

Reviewed on 6 October 2026.

Does a safety assessment distinguish the hazard of an ingredient from exposure to the finished article?

The four studies the company names each cover one endpoint on one sample, and each result describes that sample under that study's conditions.

The company publishes no hazard assessment of an input and no exposure assessment of a finished article; the Terms of Use state that a prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sample. Each of the four covers one endpoint. Each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. Irritation and sensitisation are separate endpoints answered by separate studies. Confidentiality obligations may apply to a given report. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Can an acute safety result support a claim about repeated long-term exposure?

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines.

Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does the assessment account for cumulative exposure from several products using the same material?

Exposure that adds up across several products is a long-term question, and what the company holds on health effects is four single-endpoint studies, each run on the sample submitted to it.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Are local irritation and systemic toxicity evaluated as different endpoints?

Yes: they are separate studies; Product Safety Labs, Study 65321 (OPPTS 870.1100, acute oral) and Study 65322 (OPPTS 870.1200, acute dermal) are the acute toxicity studies, and Study 65323 (OPPTS 870.2500) is the primary skin irritation study.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sample. Each of the four covers one endpoint. Each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. Irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does a negative skin-irritation result address the possibility of sensitisation?

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324.

Each was completed in 2024 and each was run on a sample. Each of the four covers one endpoint. Each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. Irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Can ingestion evidence be used to support an inhalation claim without a justified bridge?

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines.

Each study report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024.

The page names no study addressing eye exposure and no study addressing inhalation exposure, and the company does not carry a result across to an exposure route a study did not cover. A copy may be made available on our review of the request.

What the company states about what the filter gives off is in the Statement of Classification, section 2.4: “It generates no ozone and emits nothing into the air passing through it. The air leaving the filter has had nothing added to it.”

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 6 October 2026.

Does the assessment distinguish fibres, fragments and dissolved substances released from the material?

What the company says about release is about the air: the Statement of Classification states at 2.4 that the filter generates no ozone and emits nothing into the air passing through it, and that the air leaving the filter has had nothing added to it. A charge is a physical property. It is not a substance or a mixture of substances.

A statement that nothing was detected belongs to the report that measured it, with the capability of the measurement it used, and the Terms of Use state: “A reported result describes only what the identified test found.” A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.

Are particle-size distributions considered when interpreting inhalation exposure information?

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines.

Each study report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. The page names no study addressing eye exposure and no study addressing inhalation exposure, and the company does not carry a result across to an exposure route a study did not cover. The company publishes no inhalation exposure assessment, so it publishes no particle-size analysis for one. A copy may be made available on our review of the request.

What the company states about what the filter gives off is in the Statement of Classification, section 2.4: “It generates no ozone and emits nothing into the air passing through it. The air leaving the filter has had nothing added to it.”

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; Statement of Classification for the NanoFlashing™ Air Filter, section 2.4, issued by NF Technical Products Inc.

Reviewed on 6 October 2026.

Does a safety assessment cover accidental damage as well as intact use?

The label directs: “Do not install a filter whose media is torn, crushed, wet or visibly damaged.” A study covers the article it tested, so use outside those directions is assessed by the party that makes the finished article.

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.” They also state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use,” and: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The About page states that development runs configuration by configuration, and that each partner controls what is said about the work.

An assessment of a damaged article is part of the safety review the maker of the finished product carries out, and C-POLAR publishes none. The studies the company names are Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, each completed in 2024 and each run on a sample. A copy may be made available on our review of the request.

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/; C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Validation, https://cpolar.tech/validation/; NanoFlashing™ Air Filter label.

Reviewed on 6 October 2026.

Can an assessment of an upstream ingredient account for impurities formed during processing?

The property the company publishes is a charge, not a substance.

NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. A charge is a physical property. It is not a substance or a mixture of substances. The polarity is a positive electric charge at rest. It is measured as surface charge density, in nanocoulombs per square centimetre. The NanoFlashing manufacturing process produces the charge. The process acts on the filter by physical means. The charge is measured on every production run, and the measurement can be repeated on any filter, upon request.

The company publishes no assessment of an upstream input or of impurities formed in processing, and it does not set out the composition of the media; a materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, sections 2.1, 2.2, 2.3 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 21 September 2026.

Are chronic endpoints excluded explicitly when they have not been evaluated?

The four studies the company names include no chronic endpoint, and the company says so.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The company publishes no repeated-dose study, no chronic study, no genotoxicity study, no cumulative-exposure estimate and no extrapolation from one population to another, and it does not offer an acute result as any of those. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does the evidence address genotoxic potential where relevant to the intended exposure?

Genotoxicity is a separate endpoint with its own test guideline, and each of the four studies the company names reports one endpoint under the guideline its report prints.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Could an ingredient's degradation products need a different assessment from the original ingredient?

A degradation product is a different material from the one a study was run on, and each of the four studies the company names reports the endpoint it measured on the sample it was given.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Is an estimated exposure based on realistic use frequency and service duration?

Use frequency and service duration belong to a finished product in service, and each of the four studies the company names reports one endpoint on the sample it was given, under the conditions that study names.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does the assessment identify uncertainty factors rather than hide them in a safe label?

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines; each study was completed in 2024 on a sample. What it names is the record. Each of those studies describes one endpoint on that sample under the conditions it names, and none of them is an exposure assessment. The Terms of Use state: “A reported result describes only what the identified test found.”

The company publishes no exposure model, so it states no margin of safety and no uncertainty factor. An assessment that needs the assumptions behind a calculation is arranged in writing, through [email protected] on the Contact page. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.

Can an independent assessor inspect the assumptions used to calculate a margin of safety?

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines; each study was completed in 2024 on a sample. What it names is the record. Each of those studies describes one endpoint on that sample under the conditions it names, and none of them is an exposure assessment. The Terms of Use state: “A reported result describes only what the identified test found.”

The company publishes no exposure model, so it states no margin of safety and no uncertainty factor. An assessment that needs the assumptions behind a calculation is arranged in writing, through [email protected] on the Contact page. A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.

Does a non-detect for released material state the analytical detection capability?

What the company says about release is about the air: the Statement of Classification states at 2.4 that the filter generates no ozone and emits nothing into the air passing through it, and that the air leaving the filter has had nothing added to it. A charge is a physical property. It is not a substance or a mixture of substances.

A statement that nothing was detected belongs to the report that measured it, with the capability of the measurement it used, and the Terms of Use state: “A reported result describes only what the identified test found.” A materials review that needs more than the company's published pages is arranged in writing, through [email protected] on the Contact page.

Source: Statement of Classification for the NanoFlashing™ Air Filter, sections 2.4 and 3.6, issued by NF Technical Products Inc.; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.

Can an animal study be interpreted without assuming identical exposure in humans?

An animal study describes the endpoint it measured in that study, and the company does not extend it to people.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does a safety conclusion for adults identify limits on extrapolation to other populations?

A study result describes the population and the conditions that study used, and each of the four studies the company names reports one endpoint on the sample it was given.

The Validation page names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, and states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines. Each study was run on a sample, and each report prints its guideline and its completion date: Study 65321, U.S. EPA OPPTS 870.1100 (2002), 26 January 2024; Study 65322, OPPTS 870.1200 (1998), 16 January 2024; Study 65323, OPPTS 870.2500 (1998), 16 February 2024; and Study 65324, OPPTS 870.2600 (2003), by the Buehler method, 31 January 2024. A study describes the endpoint it measured, on the sample it measured, under the conditions it names.

The Terms of Use state: “A reported result describes only what the identified test found,” and: “Laboratory results report the organisms, particles, and endpoints that were measured. C-POLAR makes no clinical or medical claim from them.” A copy may be made available on our review of the request.

The studies the company names are single-endpoint studies, and it does not read them as a conclusion about long-term or repeated exposure. The Validation page states: “NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines.”

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Can a supplier distinguish no observed effect from proof that no effect is possible?

Yes: each of the four studies the company names reports its result for one endpoint, on one sample, under that study’s conditions, and none of them is offered as proof that no effect is possible.

The Validation page states that NanoFlashing™ is tested under Good Laboratory Practice to US EPA Health Effects Test Guidelines, and it names Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324. Each was completed in 2024 and each was run on a sample. Each of the four covers one endpoint. Each result describes that sample under that study’s conditions.

Each of those studies describes one endpoint, on that sample, under those conditions. Irritation and sensitisation are separate endpoints answered by separate studies. A copy may be made available on our review of the request. Confidentiality obligations may apply to a given report.

Source: C-POLAR — Validation, https://cpolar.tech/validation/; Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, 2024, US EPA Health Effects Test Guidelines; C-POLAR — Terms of Use, section 3, https://cpolar.tech/terms/.

Reviewed on 6 October 2026.

Does the assessment include emissions from the complete appliance's other components?

What a complete appliance gives off is a matter for the maker of that appliance, and C-POLAR publishes no assessment of a complete appliance. A study covers the article it tested, and the other components of a finished product are assessed by the party that puts that product together.

The Terms of Use state: “Each reported result belongs to the C-POLAR material, component, or prototype that was tested. The maker of a finished product confirms the performance of that product, because construction, processing, storage, wear, cleaning, other components, and actual use are part of it.” They also state: “Use evidence, specifications, instructions, and warnings specific to the actual finished product and use.” The About page states that development runs configuration by configuration, and that each partner controls what is said about the work.

The studies the company names are Product Safety Labs, Study 65321, Study 65322, Study 65323 and Study 65324, each completed in 2024 and each run on a sample. A copy may be made available on our review of the request. NanoFlashing™ is a technology; the name, rating and sale of a product that carries it are set by that product's maker and seller. The Terms of Use state: “A prospective partner or manufacturer must perform its own testing, validation, compatibility work, safety review, risk review, and quality controls for its proposed product and use.”

Source: C-POLAR — Terms of Use, sections 3 and 5, https://cpolar.tech/terms/; C-POLAR — About, https://cpolar.tech/about/; C-POLAR — Validation, https://cpolar.tech/validation/.

Reviewed on 6 October 2026.

Does NanoFlashing™ contain silver, copper, zinc or another metal?

C-POLAR describes NanoFlashing™ as a charge, not as a metal or any other substance.

The company does not publish the composition of the media. NanoFlashing™ is a permanent positive polarity engineered into filter media itself. It is a physical property of the filter. A charge is a physical property. It is not a substance or a mixture of substances. The company classifies the NanoFlashing™ Air Filter as a device under Section 2(h) of FIFRA, 7 U.S.C. § 136(h), and 40 C.F.R. § 152.500(a).

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, sections 2.1, 3.6 and 3.7, issued by NF Technical Products Inc.

Reviewed on 6 October 2026.

Does NanoFlashing™ contain or release nanoparticles?

C-POLAR describes NanoFlashing™ as a charge, not as particles of any size: NanoFlashing™ is a permanent positive polarity engineered into filter media itself.

It is a physical property of the filter. The name is the company's name for the technology. The company does not publish the composition of the media or a measurement of particles shed from the media, and a question about a particular filter can be sent to [email protected].

Source: C-POLAR — NanoFlashing™, https://cpolar.tech/nanoflashing/; Statement of Classification for the NanoFlashing™ Air Filter, section 2.1, issued by NF Technical Products Inc.; C-POLAR — Contact, https://cpolar.tech/contact/.

Reviewed on 6 October 2026.